MRX-7EAT Etodolac-Lidocaine Topical Patch in the Treatment of Ankle Sprains

ClinicalTrials.gov ID: NCT01198834

Public ClinicalTrials.gov record NCT01198834. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 23, 2026, 10:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Multi-Center, Double-Blind, Factorial, Comparator and Placebo-Controlled Phase III Trial to Evaluate the Efficacy, Tolerability and Safety of MRX-7EAT Etodolac-Lidocaine Topical Patch in the Treatment of Ankle Sprains

Study identification

NCT ID: NCT01198834
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: MEDRx USA, Inc.; Industry
Enrollment: 600 participants

Conditions and interventions

Conditions

Ankle Sprains

Interventions

MRX-7EAT Drug
Placebo Drug
Lidocaine Drug
Etodolac Drug

Drug

Eligibility (public fields only)

Age range: 14 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 31, 2010
Primary completion: May 31, 2011
Completion: May 31, 2011
Last update posted: Jan 16, 2018

2010 – 2011

United States locations

U.S. sites: 33
U.S. states: 18
U.S. cities: 33

Facility	City	State	ZIP	Site status
Not listed	Phoenix	Arizona	85050	—
Not listed	North Little Rock	Arkansas	72114	—
Not listed	Chico	California	95929	—
Not listed	Palm Springs	California	92262	—
Not listed	San Diego	California	92120	—
Not listed	Aurora	Colorado	80014	—
Not listed	Colorado Springs	Colorado	80907	—
Not listed	Denver	Colorado	80239	—
Not listed	Daytona Beach	Florida	32114	—
Not listed	Fort Lauderdale	Florida	33334	—
Not listed	Gulf Breeze	Florida	32561	—
Not listed	Orlando	Florida	32804	—
Not listed	West Palm Beach	Florida	33409	—
Not listed	Boise	Idaho	83702	—
Not listed	Avon	Indiana	46123	—
Not listed	Fishers	Indiana	46038	—
Not listed	Franklin	Indiana	46131	—
Not listed	Greenfield	Indiana	46140	—
Not listed	Muncie	Indiana	47304	—
Not listed	Dubuque	Iowa	52001	—
Not listed	Wichita	Kansas	67206	—
Not listed	Erlanger	Kentucky	41018	—
Not listed	Henderson	Nevada	89502	—
Not listed	Charlotte	North Carolina	28207	—
Not listed	Fargo	North Dakota	58103	—
Not listed	Cincinnati	Ohio	45246	—
Not listed	Oklahoma City	Oklahoma	73112	—
Not listed	Georgetown	Texas	78626	—
Not listed	Lubbock	Texas	79410	—
Not listed	San Antonio	Texas	78229	—
Not listed	Temple	Texas	76502	—
Not listed	Riverton	Utah	84065	—
Not listed	Danville	Virginia	24541	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01198834, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jan 16, 2018 · Synced Jul 23, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01198834 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →